The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
Open accessAbstract
BACKGROUND: Cyclophosphamide induction regimens for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis are effective in 70 to 90% of patients, but they are associated with high rates of death and adverse events. Treatment with rituximab has led to remission rates of 80 to 90% among patients with refractory ANCA-associated vasculitis and may be safer than cyclophosphamide regimens. METHODS: We compared rituximab with cyclophosphamide as induction therapy in ANCA-associated vasculitis. We randomly assigned, in a 3:1 ratio, 44 patients with newly diagnosed ANCA-associated vasculitis and renal involvement to a standard glucocorticoid regimen plus either rituximab at a dose of 375 mg per square meter of body-surface area per week for 4 weeks, with two intravenous cyclophosphamide pulses (33 patients, the rituximab group), or intravenous cyclophosphamide for 3 to 6 months followed by azathioprine (11 patients, the control group). Primary end points were sustained remission rates at 12 months and severe adverse events. RESULTS: The median age was 68 years, and the glomerular filtration rate (GFR) was 18 ml per minute per 1.73 m(2) of body-surface area. A total of 25 patients in the rituximab group (76%) and 9 patients in the control group (82%) had a sustained remission (P=0.68). Severe adverse events occurred in 14 patients in the rituximab group (42%) and 4 patients in the control group (36%) (P=0.77). Six of the 33 patients in the rituximab group (18%) and 2 of the 11 patients in the control group (18%) died (P=1.00). The median increase in the GFR between 0 and 12 months was 19 ml per minute in the rituximab group and 15 ml per minute in the control group (P=0.14). CONCLUSIONS: A rituximab-based regimen was not superior to standard intravenous cyclophosphamide for severe ANCA-associated vasculitis. Sustained-remission rates were high in both groups, and the rituximab-based regimen was not associated with reductions in early severe adverse events. (Funded by Cambridge University Hospitals National Health Service Foundation Trust and F. Hoffmann-La Roche; Current Controlled Trials number, ISRCTN28528813.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Nomenclature of Systemic Vasculitides
Jennette, J. C., Falk, R. J., Andrassy, K., Bacon, P. A., Churg, J., Gross, W. L., Hagen, E. C., Hoffman, G. S., Hunder, G. G., Kallenberg, C. G. M., et al. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370206 · Cited by 3,845
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
Stone, J. H., Merkel, P. A., Spiera, R., Seo, P., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Turkiewicz, A., Tchao, N. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909905 · Cited by 2,762
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Analysing controlled trials with baseline and follow up measurements
Vickers, A. J., & Altman, D. G. (2001) · BMJ · doi:10.1136/bmj.323.7321.1123 · Cited by 2,116
Leavitt, R. Y., Fauci, A. S., Bloch, D. A., Michel, B. A., Hunder, G. G., Arend, W. P., Calabrese, L. H., Fries, J. F., Lie, J. T., Lightfoot, R. W., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330807 · Cited by 1,947
Cohen, S. B., Emery, P., Greenwald, M. W., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., Loveless, J. E., Burmester, G., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638
Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J. W. C., Dadoniené, J., Ekstrand, A., Gaskin, G., Gregorini, G., de Groot, K., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020286 · Cited by 1,348
Self-citationModification and validation of the Birmingham Vasculitis Activity Score (version 3)
Mukhtyar, C., Lee, R., Brown, D., Carruthers, D., Dasgupta, B., Dubey, S., Flossmann, O., Hall, C., Hollywood, J., Jayne, D., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.101279 · Cited by 1,224
Self-citationJayne, D. R. W., Gaskin, G., Rasmussen, N., Abramowicz, D., Ferrario, F., Guillevin, L., Mirapeix, E., Savage, C. O. S., Sinico, R. A., Stegeman, C. A., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007010090 · Cited by 1,125
Self-citationEmery, P., Fleischmann, R., Filipowicz‐Sosnowska, A., Schechtman, J., Szczepanski, L., Kavanaugh, A., Racewicz, A. J., van Vollenhoven, R. F., Li, N. F., Agarwal, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21778 · Cited by 1,060
EULAR recommendations for the management of primary small and medium vessel vasculitis
Mukhtyar, C., Guillevin, L., Cid, M. C., Dasgupta, B., de Groot, K., Gross, W., Hauser, T., Hellmich, B., Jayne, D., Kallenberg, C. G. M., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.088096 · Cited by 990
Self-citationde Groot, K., Harper, L., Jayne, D. R. W., Flores Suarez, L. F., Gregorini, G., Gross, W. L., Luqmani, R., Pusey, C. D., Rasmussen, N., Sinico, R. A., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-10-200905190-00004 · Cited by 957
Self-citationMcHorney, C. A., Ware, J. E., Rogers, W., Raczek, A. E., & Lu, J. F. R. (1992) · Medical Care · doi:10.1097/00005650-199205001-00025 · Cited by 740
Exley, A. R., Bacon, P. A., Luqmani, R. A., Kitas, G. D., Gordon, C., Savage, C. O. S., & Adu, D. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400222 · Cited by 619
Self-citationCyclophosphamide Therapy of Severe Systemic Necrotizing Vasculitis
Fauci, A. S., Katz, P., Haynes, B. F., & Wolff, S. M. (1979) · New England Journal of Medicine · doi:10.1056/nejm197908023010503 · Cited by 526
Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study
Booth, A. D., Almond, M. K., Burns, A., Ellis, P., Gaskin, G., Neild, G. H., Plaisance, M., Pusey, C. D., & Jayne, D. R. W. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00025-8 · Cited by 504
Self-citationKeogh, K. A., Wylam, M. E., Stone, J. H., & Specks, U. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20718 · Cited by 450
Mukhtyar, C., Flossmann, O., Hellmich, B., Bacon, P., Cid, M., Cohen-Tervaert, J. W., Gross, W. L., Guillevin, L., Jayne, D., Mahr, A., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.071936 · Cited by 419
Self-citationSmith, K. G. C., Jones, R. B., Burns, S. M., & Jayne, D. R. W. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22046 · Cited by 400
Self-citationRituximab for Refractory Wegener's Granulomatosis: Report of a Prospective, Open-Label Pilot Trial
Keogh, K. A., Ytterberg, S. R., Fervenza, F. C., Carlson, K. A., Schroeder, D. R., & Specks, U. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200507-1144oc · Cited by 399
BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis
Lapraik, C., Watts, R., Bacon, P., Carruthers, D., Chakravarty, K., D’Cruz, D., Guillevin, L., Harper, L., Jayne, D., Luqmani, R., et al. (2007) · Rheumatology · doi:10.1093/rheumatology/kem146a · Cited by 369
Self-citationJones, R. B., Ferraro, A. J., Chaudhry, A. N., Brogan, P., Salama, A. D., Smith, K. G. C., Savage, C. O. S., & Jayne, D. R. W. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24637 · Cited by 350
Self-citationSteinberg, A. D., & Steinberg, S. C. (1991) · Arthritis & Rheumatism · doi:10.1002/art.1780340803 · Cited by 348
Stasi, R., Stipa, E., Del Poeta, G., Amadori, S., Newland, A. C., & Provan, D. (2006) · Rheumatology · doi:10.1093/rheumatology/kel098 · Cited by 219
Differential B- and T-cell activation in Wegener’s granulomatosis
Popa, E. R., Stegeman, C. A., Bos, N. A., Kallenberg, C. G. M., & Tervaert, J. W. C. (1999) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(99)70434-3 · Cited by 201
Suppression of human B lymphocyte function by cyclophosphamide.
Cupps, T. R., Edgar, L. C., & Fauci, A. S. (1982) · The Journal of Immunology · doi:10.4049/jimmunol.128.6.2453 · Cited by 183
BAFF is elevated in serum of patients with Wegener's granulomatosis
Krumbholz, M., Specks, U., Wick, M., Kalled, S. L., Jenne, D. E., & Meinl, E. (2005) · Journal of Autoimmunity · doi:10.1016/j.jaut.2005.08.004 · Cited by 153
Mease, P. J., Revicki, D. A., Szechiński, J., Greenwald, M., Kivitz, A., Barile-Fabris, L. A., Kalsi, J., Eames, J. R., & Leirisalo‐Repo, M. (2008) · PubMed · Cited by 93
Infectious complications of monoclonal antibodies used in cancer therapy
Rafailidis, P. I., Kakisi, O. K., Vardakas, K. Z., & Falagas, M. E. (2007) · Cancer · doi:10.1002/cncr.22666 · Cited by 86
Voswinkel, J., Müller, U., & Lamprecht, P. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1361.042 · Cited by 73
Role of Rituximab Therapy in Glomerulonephritis
Jayne, D. R. W. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008070786 · Cited by 46
Self-citation
Cited by
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
Stone, J. H., Merkel, P. A., Spiera, R., Seo, P., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Turkiewicz, A., Tchao, N. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909905 · Cited by 2,762
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Self-citationEULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
Yates, M., Watts, R. A., Bajema, I. M., Cid, M. C., Crestani, B., Hauser, T., Hellmich, B., Holle, J. U., Laudien, M., Little, M. A., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209133 · Cited by 1,194
Self-citationRituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
Guillevin, L., Pagnoux, C., Karras, A., Khouatra, C., Aumaître, O., Cohen, P., Maurier, F., Decaux, O., Ninet, J., Gobert, P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1404231 · Cited by 1,090
RETRACTED: Avacopan for the Treatment of ANCA-Associated Vasculitis
Jayne, D. R. W., Merkel, P. A., Schall, T. J., & Bekker, P. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2023386 · Cited by 1,021
Self-citationRetracted
Metadata
- Authors
- Jones, R. B., Cohen Tervaert, J. W., Hauser, T., Luqmani, R., Morgan, M. D., Peh, C. A., Savage, C. O., Segelmark, M., Tesar, V., van Paassen, P., Walsh, D., Walsh, M., Westman, K., & Jayne, D. R. W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-07-15
- Volume
- 363
- Issue
- 3
- Pages
- 211-220
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2084056567
- Cited by
- 1,748
- References
- 33
- FWCI
- 83.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.